Rare Diseases
Conference Coverage
High-dose MTX-based chemo is well tolerated in older PCNSL patients
GLASGOW – A retrospective, real-world study suggests that older, fit patients can tolerate an intensive treatment regiment for primary central...
Conference Coverage
Creating CAR T-cell therapies for T-cell malignancies
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
Conference Coverage
Tumor-treating fields boost chemo for mesothelioma
GENEVA - Patients with malignant pleural mesothelioma who were treated with TTFields in combination with pemetrexed and...
From the Journals
Bendamustine/rituximab combo proves viable for comorbid CLL
Combination bendamustine and rituximab offers an effective treatment option for older, sicker patients with chronic lymphocytic leukemia.
Conference Coverage
Genetic variant increases stroke risk in childhood cancer survivors
ATLANTA - Dr. Yadav Sapkota of St. Jude Children's Research Hospital discusses the identification of a genetic variant that is strongly associated...
Conference Coverage
CAR T cells target HER2 expression in advanced sarcomas
ATLANTA – Although HER2 expression in osteosarcoma and rhabomyosarcoma is too low for HER2-targeted therapies such...
From the Journals
Case report may link gluteal implants to lymphoma
On the heels of increased reports of breast implant–related anaplastic large cell lymphoma, researchers report a case of lymphoma that may be...
Conference Coverage
Lentiviral gene therapy appears effective in X-CGD
HOUSTON – Results from the small study provide a “proof of concept” for the use of gene therapy in X-linked chronic granulomatous disease,...
From the Journals
Similar results for once- or twice-weekly carfilzomib in MM
There was no significant difference in safety or survival outcomes among patients with newly diagnosed multiple myeloma.
From the Journals
Trial supports less aggressive myeloma treatment
A less intensive transplant and maintenance strategy proved equally effective as more aggressive approaches in patients with multiple myeloma.
News
FDA approves caplacizumab for aTTP
The injection is approved in combination with plasma exchange and immunosuppressive therapy for adults with acquired thrombotic thrombocytopenia...